GAMMA Investing LLC Invests $41,000 in BioLife Solutions, Inc. (NASDAQ:BLFS)

GAMMA Investing LLC bought a new stake in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) during the 4th quarter, Holdings Channel.com reports. The firm bought 2,394 shares of the medical equipment provider’s stock, valued at approximately $41,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC lifted its stake in shares of BioLife Solutions by 167.2% during the fourth quarter. Nisa Investment Advisors LLC now owns 1,630 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 1,020 shares in the last quarter. Allspring Global Investments Holdings LLC raised its holdings in shares of BioLife Solutions by 88.4% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 11,346 shares of the medical equipment provider’s stock valued at $157,000 after buying an additional 5,324 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in BioLife Solutions by 8.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,622 shares of the medical equipment provider’s stock worth $216,000 after acquiring an additional 1,164 shares in the last quarter. Dark Forest Capital Management LP purchased a new position in BioLife Solutions in the 3rd quarter worth approximately $223,000. Finally, Illinois Municipal Retirement Fund acquired a new stake in BioLife Solutions in the third quarter valued at approximately $270,000. 93.24% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Jefferies Financial Group initiated coverage on shares of BioLife Solutions in a research report on Thursday, April 4th. They set a “buy” rating and a $22.00 target price on the stock. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $23.40.

BioLife Solutions Stock Performance

Shares of BLFS stock opened at $18.03 on Friday. BioLife Solutions, Inc. has a 12 month low of $8.92 and a 12 month high of $24.50. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.86 and a quick ratio of 1.83. The firm has a market capitalization of $816.76 million, a P/E ratio of -11.86 and a beta of 1.69. The company’s fifty day moving average price is $17.37 and its two-hundred day moving average price is $15.64.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings data on Thursday, February 29th. The medical equipment provider reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.02. BioLife Solutions had a negative net margin of 46.37% and a negative return on equity of 13.36%. The firm had revenue of $32.73 million for the quarter, compared to analyst estimates of $32.70 million. On average, research analysts anticipate that BioLife Solutions, Inc. will post -0.6 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other BioLife Solutions news, CEO Greef Roderick De sold 7,249 shares of the business’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $16.60, for a total value of $120,333.40. Following the transaction, the chief executive officer now owns 461,854 shares in the company, valued at approximately $7,666,776.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Sarah Aebersold sold 4,000 shares of the company’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $17.65, for a total value of $70,600.00. Following the sale, the insider now owns 65,843 shares in the company, valued at approximately $1,162,128.95. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Greef Roderick De sold 7,249 shares of the company’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $16.60, for a total transaction of $120,333.40. Following the completion of the sale, the chief executive officer now owns 461,854 shares in the company, valued at approximately $7,666,776.40. The disclosure for this sale can be found here. Insiders have sold 33,996 shares of company stock worth $562,145 in the last quarter. 2.70% of the stock is owned by corporate insiders.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.